Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics.

Leukemia 2005 May;19(5):792-8

Institut de Recherche contre le Cancer, Inserm U524, Lille, France.

Idiopathic hypereosinophilic syndrome (HES) characterized by unexplained and persistent hypereosinophilia is heterogeneous and comprises several entities: a myeloproliferative form where myeloid lineages are involved with the interstitial chromosome 4q12 deletion leading to fusion between FIP1L1 and PDGFRA genes, the latter acquiring increased tyrosine kinase activity. And a lymphocytic variant, where hypereosinophilia is secondary to a primitive T lymphoid disorder demonstrated by the presence of a circulating T-cell clone. We performed molecular characterization of HES in 35 patients with normal karyotype by conventional cytogenetic analysis. TCRgamma gene rearrangements suggesting T clonality were seen in 11 (31%) patients, and FIP1L1-PDGFRA by RT-PCR in six (17%) of 35 patients, who showed no evidence of T-cell clonality. An elevated serum tryptase level was observed in FIP1L1-PDGFRA-positive patients responding to imatinib, whereas serum IL-5 levels were not elevated in T-cell associated hypereosinophilia. Sequencing FIP1L1-PDGFRA revealed scattered breakpoints in FIP1L1-exons (10-13), whereas breakpoints were restricted to exon 12 of PDGFRA. In the 29 patients without FIP1L1-PDGFRA, no activating mutation of PDGFRA/PDGFRB was detected; however; one patient responded to imatinib. FISH analysis of the 4q12 deletion was concordant with FIP1L1-PDGFRA RT-PCR data. Further investigation of the nature of FIP1L1-PDGFRA affected cells will improve the classification of HES.

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.leu.2403722DOI Listing
May 2005
4 Reads

Publication Analysis

Top Keywords

hypereosinophilic syndrome
8
patients normal
8
fip1l1-pdgfra rt-pcr
8
patients fip1l1-pdgfra
8
idiopathic hypereosinophilic
8
4q12 deletion
8
molecular characterization
8
patients
6
fip1l1-pdgfra
5
evidence t-cell
4
t-cell clonality
4
patients evidence
4
17% patients
4
clonality elevated
4
imatinib serum
4
rt-pcr 17%
4
serum tryptase
4
observed fip1l1-pdgfra-positive
4
patients responding
4
level observed
4

References

(Supplied by CrossRef)

TR Golub et al.
Cell 1994

TS Ross et al.
Blood 1998

S Kulkarni et al.
Cancer Res 2000

MK Magnusson et al.
Blood 2001

K Wilkinson et al.
Blood 2003

F Roufosse et al.
Annu Rev Med 2003

JM Goldman et al.
N Engl J Med 2003

MC Heinrich et al.
Science 2003

EJ Baxter et al.
Hum Mol Genet 2002

PM Irusta et al.
EMBO J 1998

J Cortes et al.
Blood 2003

Similar Publications